Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis

P.C.M. van de Kerkhof; Christopher Em Griffiths; Kristian Reich; Craig L. Leonardi; Andrew Blauvelt; Tsen‐Fang Tsai; Yankun Gong; Jiaqing Huang; C. Papavassilis; Todd Fox

doi:10.1016/j.jaad.2016.03.024

Back

Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis

Article 2016 en

Related publications

Article2011

Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies

Kristian Reich, Richard G. Langley, Mark Lebwohl, Philippe Szapary, Cynthia Guzzo, Newman Yeilding, S. Li, M-C. Hsu, Christopher Em Griffiths

Article2018

Secukinumab's Pooled and Long-Term Safety: Analysis of 19 Psoriasis Clinical Trials Up to 5 Years of Treatment

PCM van de Kerkhof, Kristian Reich, C Leonardi, Andrew Blauvelt, Nehal Nailesh Mehta, TF Tsai, R. You, Phil Papanastasiou, M. Milutinovic, Christopher Em Griffiths

Article2020

Clinical efficacy and safety of secukinumab in patients with psoriasis and comorbidities: pooled analysis of 4 phase 3 clinical trials

Alice B. Gottlieb, Jashin J. Wu, Christopher Em Griffiths, Kwaku Marfo, Elisa Muscianisi, Xiangyi Meng, Jennifer Frueh, Mark Lebwohl

Article2017

Efficacy of guselkumab in subpopulations of patients with moderate‐to‐severe plaque psoriasis: a pooled analysis of the phase <scp>III VOYAGE</scp> 1 and <scp>VOYAGE</scp> 2 studies

Kenneth B. Gordon, Andrew Blauvelt, Peter Foley, Michael Song, Yasmine Wasfi, B. Randazzo, Yaung‐Kaung Shen, Yin You, Christopher Em Griffiths

Article2013

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up

Kim Papp, Christopher Em Griffiths, Kenneth B. Gordon, Mark Lebwohl, Philippe Szapary, Yasmine Wasfi, Daphne Chan, M.-C. Hsu, Vincent Ho, Pierre‐Dominique Ghislain, Bruce Strober, Kristian Reich

Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis

Discussion(0)

Related publications

Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies

Secukinumab's Pooled and Long-Term Safety: Analysis of 19 Psoriasis Clinical Trials Up to 5 Years of Treatment

Clinical efficacy and safety of secukinumab in patients with psoriasis and comorbidities: pooled analysis of 4 phase 3 clinical trials

Efficacy of guselkumab in subpopulations of patients with moderate‐to‐severe plaque psoriasis: a pooled analysis of the phase <scp>III VOYAGE</scp> 1 and <scp>VOYAGE</scp> 2 studies

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up